Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO 2:4: Tolvaptan in ADPKD
NCT00413777Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2005
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs). Started Dec 2005; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT00413777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413777.